General
Ganeden-GB30 which was originally isolated as a Lactobacillus, enjoys a longer history of safe use than most of the common Lactobacillus or Bifid bacterium species that are commonly sold at health food stores or used in the production of cultured dairy products.
The bacteria is known as a strain of Bacillus coagulans (B. coagulans).
Important safety features of GanedenBC30 that will be explained below:
- Safe history of use in products for over 50 years
- Used by Ganeden Biotech:
- Over 5 years in oral administration
- Safely used in over 4 million boxes of Ganeden Products with not one reported adverse reaction over the last 4 years
- Easily controlled by all common antibiotics
- Naturally flushed out of the body
No references have been found implicating Bacillus coagulans as a primary causative organism of any diseases.
Easy Eradication
B. coagulans does not produce the extra-cellular substances that contribute to epithelial adhesion. Depending on the peristaltic rate of each individual, the number of cells will decline to virtually zero over a five day period. The rate of this decline is heavily weighted on the first two days. For this reason, in order to maintain the benefit of the Bacteria in its various internal applications – additional cells (in the form of an additional caplet), must be ingested every 24-36 hours in order to augment the number of cells that remain in the Brush-Boarder area.
ReferencesDocumentation Supporting The Safety Of Orally Administered Products Containing Lactic Acid Producing Bacteria: Adams MR. Safety of industrial lactic acid bacteria. J Biotechnol 1999 Feb 19; 68(2-3):171-8.
Donahue DC, Salminen S, Safety of Probiotic Bacteria, Asia Pacific Journal of Clinical Nutrition 1996; 5:25-28.
Gibson G, Fuller R. Aspects of in vitro and in vivo research approaches directed toward identifying probiotics and probiotics for human use. Symposium: Probiotic Bacteria: Implications for Human Health. Experimental Biology 99 Meeting. April 17-21, Washington DC.
Green DH, Wakeley PR, Page A, et al. Characterization of two Bacillus probiotics. Applied and Environmental Microbiology 1999; Sep: 4 288-4291.
Guarner F, Schaafsma GJ. Probiotics (Short Communication). International Journal of Food and Microbiology. 1997; Nov: 237-238.
Ishibashi N, Yamazaki S. Probiotics and Safety. Am J Clin Nutr 2001 Feb;73(2 Suppl):465S-470S.
Marteau PR, de Vrese M, Cellier CJ, Schrezenmeir J. Protection from gastrointestinal disease with use of probiotics. Am J Clin Nutr 2001;73(suppl):430S-6S.
Pelto L, Isolauri E, Nuutila J, et al. Probiotic bacteria down-regulate the milk-induced inflammatory response in milk-hypersensitive subjects but have an immunostimulatory effect in healthy subjects. Clinical and Experimental Allergy. 1998;28:1474-1479.
Saarela M, Mogensen G, Fonden R, Matto J, Mattila-Sandholm T. Probiotic bacteria: safety and technological properties. J Biotechnology 2000 Dec 28;84(3):197-215.
Salesmen S, von Wright A, Morella L, et al. Demonstration of safety of probiotics – a review. International Journal of Food Microbiology 1998;44:93-106.
Sanders ME, Hues isn’t Veldt J. Bringing probiotic-containing functional food to the market: microbiological, product, regulatory labeling issues. Antonie van Leeuwenhoek 1999;76:293-315.
Wagner RD, Warner T, Roberts L, Farmer J, Balish E. Colonization of congenitally immunodeficient mice with probiotic bacteria. Infect Immun 1997 Aug;65(8):3345-51.
